BioAge Labs, Inc. (BIOA) Revenue by Segment & Business Profile
Therapeutic product development for metabolic diseases was 100.0% of BioAge Labs, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BIOABioAge Labs, Inc.Follow BIOA — free
—
Price chart with a free account
- Market cap
- 234.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What the company does
BioAge Labs, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. Trailing twelve-month revenue: $10.4 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical-stage pharma
BioAge Labs, Inc. — questions
- What does BioAge Labs, Inc. do?
- BioAge Labs, Inc. is a drug manufacturers - specialty & generic company in the healthcare sector. Trailing twelve-month revenue: $10.4 million as of 2026-06-30.
- How does BioAge Labs, Inc. make money?
- By the lines it reports in its SEC filings: Therapeutic product development for metabolic diseases 100.0% of revenue.
Every figure on this page comes from BioAge Labs, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.